Axe Compute (AGPU) Registration Filing summary

Company overview and business model

• Applies artificial intelligence and a proprietary biobank of over 150,000 tumor samples to optimize oncology drug discovery and development, offering services from early discovery to clinical trials.

• Operates a digital asset treasury strategy focused on Aethir (ATH) tokens, aiming to generate yield through staking and liquidity activities, with significant balance sheet allocation to ATH.

• PEDAL platform provides early insights for biopharma clients to prioritize oncology portfolios and repurpose failed drug compounds.

Financial performance and metrics

• As of October 21, 2025, held approximately 5.45 billion ATH tokens valued at $174.4 million.

• Recent private placements raised $413,093 (August) and $50.77 million (September) in gross proceeds, plus in-kind ATH contributions valued at $292.7 million (discounted to $173.3 million).

• Audit reports raise substantial doubt about ability to continue as a going concern due to recurring losses and accumulated deficit.

Use of proceeds and capital allocation

• Proceeds from warrant exercises will be used for the Treasury Strategy, working capital, and general corporate purposes.

• Net proceeds from the September offerings are primarily allocated to acquiring ATH tokens and supporting the Treasury Strategy.